Peytant Solutions Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $275K
Latest Deal Amount
  • Investors
  • 3

Peytant Solutions General Information

Description

Developer of a medical implant designed to offer rapid bio-integration in the treatment of all luminal diseases. The company's implant incorporates regenerative human biomaterial with absorbable and alloy implant technologies and offers a regenerative human biomaterial platform for technologies used in the treatment of luminal diseases, enabling doctors to treat luminal diseases with a high success rate.

Contact Information

Website
www.peytant.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 3650 Annapolis Lane North
  • Suite 180
  • Plymouth, MN 55447
  • United States
+1 (763) 000-0000

Peytant Solutions Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Peytant Solutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 23-Mar-2021 $275K 00.000 Completed Product Development
6. Debt - PPP 11-Apr-2020 00000 00.000 Completed Product Development
5. Accelerator/Incubator 28-Sep-2017 00000 00.000 Completed Product Development
4. Later Stage VC (Series B) 27-Jul-2017 00.000 00.000 00.00 Completed Product Development
3. Angel (individual) 01-Nov-2015 Cancelled Product Development
2. Later Stage VC (Series A) 03-Sep-2015 $576K $576K 00.000 Completed Product Development
1. Grant 01-Jan-2010 $71.5K Completed Product Development
To view Peytant Solutions’s complete valuation and funding history, request access »

Peytant Solutions Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 000,000 00.000000 00.0 00.0 00 00.0 00.000
To view Peytant Solutions’s complete cap table history, request access »

Peytant Solutions Patents

Peytant Solutions Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9205177-B2 Stents modified with material comprising amnion tissue and corresponding processes Active 04-Mar-2009 0000000000 0
US-20100228335-A1 Stents modified with material comprising amnion tissue and corresponding processes Granted 04-Mar-2009 0000000000 00
JP-2012519543-A Stent modified with a material comprising amnion tissue and corresponding method Granted 04-Mar-2009 0000000000 0
JP-5693475-B2 Stent modified with a material comprising amnion tissue and corresponding method Active 04-Mar-2009 0000000000
EP-2403438-A2 Stents modified with material comprising amnion tissue and corresponding processes Granted 04-Mar-2009 A61L31/005 0

Peytant Solutions Executive Team (2)

Name Title Board Seat Contact Info
John Schorgl Co-Founder, Chief Executive Officer & Chairman
Steven Healy Co-Founder & Board Member
To view Peytant Solutions’s complete executive team members history, request access »

Peytant Solutions Board Members (6)

Name Representing Role Since
Bruce Faulken Peytant Solutions Board Member 000 0000
Clay Anselmo Peytant Solutions Board Member 000 0000
Craig Walker MD Peytant Solutions Board Member 000 0000
Jeffrey Chambers MD Peytant Solutions Board Member 000 0000
John Schorgl Peytant Solutions Co-Founder, Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Peytant Solutions Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
University Enterprise Laboratories Accelerator/Incubator 000 0000 000000 0
Robert Thatcher Angel (individual) Minority 000 0000 000000 0
Steven Healy Angel (individual) Minority 000 0000 000000 0
To view Peytant Solutions’s complete investors history, request access »